Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Posts Tagged ‘NASDAQ:SNTS’
Santarus, Inc. (SNTS), Nuance Communications Inc. (NUAN), Baidu.com, Inc. (ADR) (BIDU): Here’s What This $17 Billion Money Manager Has Been Buying
Today, let's look at Fred Alger Management, founded in 1964, and managing mutual funds, pension funds, and more.
Santarus, Inc. (SNTS), Pharmacyclics, Inc. (PCYC), Ariad Pharmaceuticals, Inc. (ARIA): Should You Jump on This Biotech After Profit-Taking?
After a truly remarkable 20-month 650% gain, shares of Santarus, Inc. (NASDAQ:SNTS) have fallen by more than 20% since its all-time high in early August.
PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?
In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.
Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Santarus, Inc. (SNTS), Aegerion Pharmaceuticals, Inc. (AEGR), Ariad Pharmaceuticals, Inc. (ARIA): Did a Strong New Drug Make This Biotech Overvalued?
Santarus, Inc. (NASDAQ:SNTS) has risen over 300% in the past year partly based on sales optimism for ulcerative colitis drug Uceris, which launched in the first quarter.
What Hedge Funds Think About VIVUS, Inc. (VVUS)
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market.
Regeneron Pharmaceuticals Inc (REGN), Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ): Have These 3 Biotechs Reached A Peak?
On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection.
Santarus, Inc. (SNTS), Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ): Three Earning Catalysts That Could Push This Biotech Even Higher
Santarus, Inc. (NASDAQ:SNTS) has traded higher by 250% over the last year, and much of those gains have been created after the company’s last two quarterly reports.
Santarus, Inc. (SNTS), Cytec Industries Inc (CYT), TD Ameritrade Holding Corp. (AMTD): Four Noteworthy Upgrades on Monday
Stocks get upgraded every day, but some are more impactful and meaningful than others, which is why I’m looking at those that may have the most meaning.
XPO Logistics Inc (XPO), Restoration Hardware Holdings Inc (RH): Top Value Stocks for the Next Six Months
What are the best opportunities for the second half of 2013 -- and why is there so much upside? Rather than my “Value of the Month” article, I am focusing on five stocks that...
Santarus, Inc. (SNTS), Pacira Pharmaceuticals Inc (PCRX): Make Money in These Growing Pharma Stocks the Easy Way
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
Santarus, Inc. (SNTS): Insiders Are Buying, Should You?
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
This Metric Says You Are Smart to Buy Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Santarus, Inc. (SNTS) Is a Real Gas!
Investing in the stock market can sometimes be a gut wrenching experience. However, for investors in Santarus, Inc.
Santarus, Inc. (SNTS): Passive Hedge Fund Just Upped Its Stake By 149%
A market-moving update, Jacob Gottlieb's Visium Asset Management purchased 2,294,704 shares of Santarus, Inc.
Here is What Hedge Funds Think About Santarus, Inc. (SNTS) – PDL BioPharma Inc. (PDLI), Sarepta Therapeutics Inc (SRPT)
In the eyes of most traders, hedge funds are perceived as unimportant, old financial tools of years past.
PDL BioPharma Inc. (NASDAQ:PDLI): Insiders Are Dumping, Should You? – Santarus, Inc. (NASDAQ:SNTS), VIVUS, Inc. (NASDAQ:VVUS)
In the 21st century investor’s toolkit, there are a multitude of indicators investors can use to track publicly traded companies.
Correcting the Process of Overreaction in the Market: Bank of America Corp (BAC), Seagate Technology PLC (STX)
It’s no secret that retail investors make an abundance of costly mistakes. The sad thing is that very few actually learn from these mistakes.
3 Horrendous Health-Care Stocks This Week: Impax Laboratories Inc (IPXL), Depomed Inc (DEPO), AngioDynamics, Inc. (ANGO)
Mr. Market was a happy camper this week, with the Dow setting all-time highs. However, a few stocks in the health-care sector didn't join the party.
2 to Buy & 1 to Sell After Earnings on Monday: Stratasys, Ltd. (SSYS), Santarus, Inc. (SNTS), Myriad Genetics, Inc. (MYGN)
Monday was a somewhat slow day in terms of companies reporting earnings; however like all days during earnings season, opportunity still presented itself.
